1. Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab;Abbas;EJNMMI Res.,2011
2. Measurement of the 211Pb half-life using recoil atoms from 219Rn decay;Aitken-Smith;Appl. Radiat. Isot.,2016
3. The solution of a system of differential equations occurring in the theory of radioactive transformations;Bateman;Proc. Camb. Philos. Soc.,1910
4. Bayer, 2015. Safety and tolerability of BAY1862864 injection in subjects with relapsed or refractory CD22-positive non-Hodgkin’s lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2016 Mar 17]. Available from: 〈https://www.clinicaltrials.gov/ct2/show/NCT02581878〉 NLM identifier: NCT02581878.
5. Bayer, 2018. First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2018 Sep 14]. Available from: 〈https://www.clinicaltrials.gov/ct2/show/NCT03507452〉 NLM identifier: NCT03507452.